GLP-1 receptor agonists have transformed the therapeutic landscape for both type 2 diabetes mellitus and obesity, primarily by modulating appetite and gastric emptying to facilitate weight loss [1]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.